Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double Blind, Randomised, Dose Titration, Placebo Controlled, Multicentre Clinical Trial

Trial Profile

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double Blind, Randomised, Dose Titration, Placebo Controlled, Multicentre Clinical Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2015

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Sponsors Bial
  • Most Recent Events

    • 03 May 2014 Tolerability results from a pooled analysis of 5 trials in elderly patients who participated in non-epilepsy studies presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 26 Sep 2013 Pooled analysis presented at the 21st World Congress of Neurology.
    • 26 Sep 2013 Primary endpoint 'Young-Mania-Rating-Scale' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top